Serum Levels of Sirtuin-1 in Patients with Lung Cancer and its Association with Karnofsky Performance Status: Sirtuin-1 in lung cancer

Saeed  Hosseninia; Aslan  Ameli; Mohammad Reza  Aslani; Farhad  Pourfarzi; Hassan Ghobadi

doi:10.23750/abm.v92i2.10712

Serum Levels of Sirtuin-1 in Patients with Lung Cancer and its Association with Karnofsky Performance Status

Sirtuin-1 in lung cancer

Authors

Saeed Hosseninia Internal Medicine Department (Pulmonary Division), Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Aslan Ameli Internal Medicine Department, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Mohammad Reza Aslani 3Lung Inflammatory Diseases Research Center, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Farhad Pourfarzi Digestive Disease Research Center, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Hassan Ghobadi a:1:{s:5:"en_US";s:125:"Internal Medicine Department (Pulmonary Division), Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran";}

DOI: https://doi.org/10.23750/abm.v92i2.10712

Keywords:

Lung cancer, Sirtuin-1, Quality of life, Karnofsky performance status.

Abstract

Background: Lung cancer is a major cause of cancer-related deaths worldwide. There are conflicting results regarding the role of sirtuin-1 in cancer. This study aimed to evaluate the serum sirtuin-1 levels in patients with lung cancer and its relationship with the quality of life based on Karnofsky performance statue scale (KPS).

Methods: Serum sirtuin-1 levels were measured in 30 male patients with lung cancer and 50 healthy men. The two groups were matched for age. The difference between the serum levels of sirtuin-1 between the two groups and its relationship with KPS and other clinical parameters were evaluated. Data were analyzed by independent t-test and Pearson correlation, and P < 0.05 was considered as significant.

Results: Sirtuin-1 levels were significantly lower in the patients in comparison with healthy subjects (P < 0.001). There was also a significant relationship between the serum level of sirtuin-1 with KPS (P < 0.001, r = 0.634), arterial oxygen saturation (P < 0.01, r = 0.470), and smoking history (P < 0.01, r = -0.330). In addition, the serum sirtuin-1 levels were significantly lower in adenocarcinoma than that in squamous cell carcinoma or small cell lung cancer (p < 0.001 and P < 0.05, respectively).

Conclusion: The serum levels of sirtuin-1 were lower in patients with lung cancer. In addition, there was a significant correlation between serum levels of sirtuin-1 and KPS, O2 saturation, and smoking history. Further serological and histological studies seem to be necessary due to the existence of conflicting reports regarding sirtuin-1.

References

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709-19.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907.
3. Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician. 2015;91(4):250-6.
4. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019;85(1).
5. Vardanjani HM, Zeinali M, Radmerikhi S, Hadipour M. Lung cancer prevalence in Iran by histologic subtypes. Advanced biomedical research. 2017;6.
6. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-62.
7. Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015;15(10):608-24.
8. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305(5682):390-2.
9. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett. 2011;306(1):10-4.
10. Jang SH, Min KW, Paik SS, Jang KS. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol. 2012;65(8):735-9.
11. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612-8.
12. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751-9.
13. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007;299(2):103-6.
14. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14(4):312-23.
15. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69(5):1702-5.
16. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.
17. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32(10):1523-31.
18. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009;41(4):366-71.
19. Latifkar A, Ling L, Hingorani A, Johansen E, Clement A, Zhang X, et al. Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity. Dev Cell. 2019;49(3):393-408.e7.
20. Sun L, Li H, Chen J, Dehennaut V, Zhao Y, Yang Y, et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst. 2013;105(12):887-98.
21. Sun L, Li H, Chen J, Iwasaki Y, Kubota T, Matsuoka M, et al. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J Cell Sci. 2013;126(Pt 17):3939-47.
22. Aslani MR, Matin S, Nemati A, Mesgari Abbasi M, Ghorbani S, Ghobadi H. Effects of conjugated linoleic acid supplementation on serum levels of interleukin-6 and sirtuin 1 in COPD patients. Avicenna Journal of Phytomedicine. 2019.
23. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. Embo j. 2002;21(23):6539-48.
24. Gao Z, Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun. 2008;376(4):793-6.
25. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 2013;3(4):1175-86.
26. Gharabaghi MA. Diagnostic investigation of BIRC 6 and SIRT 1 protein expression level as potential prognostic biomarkers in patients with non‐small cell lung cancer. The clinical respiratory journal. 2018;12(2):633-8.
27. Wang J, Wang C. Prognostic and Predictive Role of Sirtuin1 Expression in Lung Adenocarcinoma. Clin Lab. 2016;62(10):1989-94.
28. Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin A-M, Larráyoz M, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015;10(4):e0124670.
29. Yanagisawa S, Papaioannou AI, Papaporfyriou A, Baker JR, Vuppusetty C, Loukides S, et al. Decreased Serum Sirtuin-1 in COPD. Chest. 2017;152(2):343-52.